COA licensing readiness belongs in protocol planning

Choosing a clinical outcome assessment is a scientific decision with operational consequences. An instrument may fit the endpoint while its permission, exact version, required languages or electronic implementation remain unresolved. If those dependencies surface after build planning, they can create rework and put study timelines under pressure.

Why licensing readiness affects more than contracting

COA readiness sits between scientific strategy and study delivery. A permission question can affect whether an instrument may be used. A missing language version can affect a country plan. A different delivery mode can trigger electronic implementation, migration or review requirements. Each decision can also change the work expected from the sponsor, instrument owner, translation provider and eCOA vendor.

A single overall “green” status can hide these details. Study teams need visibility at instrument, version, language and mode level before they commit to build and launch dates.

What a decision-ready COA review should cover

For each assessment, the readiness record should connect:

• Scientific context: exact instrument and version, intended population, concept of interest and endpoint role.
• Rights and permissions: relevant owner or authorised licensing contact, permitted use, agreement status and supporting evidence.
• Countries and languages: required variants, available versions, translation status and gaps requiring confirmation.
• Delivery mode: paper, electronic or other administration requirements and any migration or implementation review.
• Study technology: eCOA build inputs, screenshots, formatting, device presentation and dependencies with the selected provider.
• Ownership and timing: accountable owner, next action, target date, blocker and evidence required to declare readiness.

Status should be based on evidence. “Information requested” is different from “permission confirmed,” and “translation available” is different from “approved for the study’s intended use and delivery mode.”

How Luminova can support your team

Depending on the portfolio and study stage, we can support:

• an instrument, version, country, language and delivery-mode readiness matrix;
• identification of rights-holder, licensing-contact and evidence gaps;
• review of translation, electronic migration and eCOA implementation dependencies;
• alignment of COA readiness with protocol milestones and build planning;
• a prioritised issue and action register with owners and target dates;
• coordination inputs for sponsor, CRO, instrument owner and eCOA-provider discussions; and
• readiness reporting that distinguishes open questions, confirmed decisions and implementation evidence.

The aim is to give the study team one dependable view of readiness and the specific actions needed to protect the delivery plan.

Review readiness at the decisions that change scope

A COA readiness review is useful during protocol planning, before eCOA build initiation and before country activation decisions. It should also be revisited when a country, language, instrument, version or delivery mode changes. Those decisions can create new licensing and implementation dependencies even when the endpoint strategy remains the same.

Bring the study lead, COA specialist, licensing owner and eCOA delivery lead around the same record. For each unresolved item, agree who can provide the answer, what evidence will close it and when the decision is required.

Keep scientific fit and operational readiness connected

FDA’s final October 2025 guidance describes the evidence needed to support selection, development or modification of a fit-for-purpose COA. Instrument familiarity or availability does not, by itself, establish scientific fit. Operational readiness should be tracked alongside that assessment rather than substituted for it. FDA PFDD Guidance 3.

C-Path’s Translations & Licensing Management resources connect licensing, translation and electronic migration activities. This supports a joined-up readiness approach rather than separate trackers that reveal dependencies late. C-Path TLM resources.

Technology provides control; qualified confirmation establishes readiness

Pragma Clinical’s COA Licensing module can support case management, owner contacts, activity records and status reporting. Luminova combines this structure with clinical technology review and coordination. The relevant instrument owner or authorised party must still confirm permissions and applicable conditions.

Readiness conclusions depend on the exact instrument, version, intended use, countries, languages, delivery mode and confirmation from the relevant rights holder or authorised party.